AU2018259078B2 - C5-anilinoquinazoline compounds and their use in treating cancer - Google Patents

C5-anilinoquinazoline compounds and their use in treating cancer Download PDF

Info

Publication number
AU2018259078B2
AU2018259078B2 AU2018259078A AU2018259078A AU2018259078B2 AU 2018259078 B2 AU2018259078 B2 AU 2018259078B2 AU 2018259078 A AU2018259078 A AU 2018259078A AU 2018259078 A AU2018259078 A AU 2018259078A AU 2018259078 B2 AU2018259078 B2 AU 2018259078B2
Authority
AU
Australia
Prior art keywords
compound
triazol
acetamide
formula
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018259078A
Other languages
English (en)
Other versions
AU2018259078A1 (en
Inventor
Tudor GRECU
Jason Grant Kettle
Martin John Packer
Stuart Eric Pearson
James Michael Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2018259078A1 publication Critical patent/AU2018259078A1/en
Application granted granted Critical
Publication of AU2018259078B2 publication Critical patent/AU2018259078B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018259078A 2017-04-27 2018-04-26 C5-anilinoquinazoline compounds and their use in treating cancer Active AU2018259078B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490859P 2017-04-27 2017-04-27
US62/490,859 2017-04-27
PCT/EP2018/060798 WO2018197642A1 (en) 2017-04-27 2018-04-26 C5-anilinoquinazoline compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
AU2018259078A1 AU2018259078A1 (en) 2019-10-17
AU2018259078B2 true AU2018259078B2 (en) 2021-10-07

Family

ID=62091877

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018259078A Active AU2018259078B2 (en) 2017-04-27 2018-04-26 C5-anilinoquinazoline compounds and their use in treating cancer

Country Status (13)

Country Link
US (2) US10273227B2 (enExample)
EP (1) EP3615522B1 (enExample)
JP (1) JP7128204B2 (enExample)
KR (1) KR102603153B1 (enExample)
CN (1) CN110573505B (enExample)
AR (1) AR111494A1 (enExample)
AU (1) AU2018259078B2 (enExample)
CA (1) CA3059283A1 (enExample)
ES (1) ES2888298T3 (enExample)
MX (1) MX389244B (enExample)
RU (1) RU2769694C2 (enExample)
TW (1) TWI774758B (enExample)
WO (1) WO2018197642A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
WO2022053657A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
KR20230064560A (ko) * 2021-10-29 2023-05-10 보로노이바이오 주식회사 퀴나졸린 유도체 화합물 및 이의 용도
MX2024007044A (es) * 2021-12-09 2024-09-04 Deciphera Pharmaceuticals Llc Compuestos heterociclicos como inhibidores de kit quinasa.
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178382A1 (en) * 2003-06-17 2006-08-10 Astrazeneca Ab Chinazoline derivatives as aurora kinase inhibitors
US7709479B1 (en) * 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070106549A1 (en) 2005-11-04 2007-05-10 Stocking Christine A Turnkey aviation budget management
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009140549A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN103254142B (zh) 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104130200B (zh) 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
US11053223B2 (en) 2017-04-27 2021-07-06 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709479B1 (en) * 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
US20060178382A1 (en) * 2003-06-17 2006-08-10 Astrazeneca Ab Chinazoline derivatives as aurora kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMMEDCHEM, 2013, vol. 8, no. 6, pages 928 - 933 *

Also Published As

Publication number Publication date
US20190263787A1 (en) 2019-08-29
US20180312490A1 (en) 2018-11-01
MX389244B (es) 2025-03-20
EP3615522B1 (en) 2021-08-04
JP2020517677A (ja) 2020-06-18
AU2018259078A1 (en) 2019-10-17
KR102603153B1 (ko) 2023-11-15
KR20190141203A (ko) 2019-12-23
JP7128204B2 (ja) 2022-08-30
BR112019022229A2 (pt) 2020-05-12
US10273227B2 (en) 2019-04-30
RU2019136279A (ru) 2021-05-27
TW201904960A (zh) 2019-02-01
CN110573505A (zh) 2019-12-13
EP3615522A1 (en) 2020-03-04
RU2019136279A3 (enExample) 2021-05-31
ES2888298T3 (es) 2022-01-03
MX2019012847A (es) 2022-01-07
CA3059283A1 (en) 2018-11-01
US10829479B2 (en) 2020-11-10
TWI774758B (zh) 2022-08-21
WO2018197642A1 (en) 2018-11-01
CN110573505B (zh) 2023-04-11
AR111494A1 (es) 2019-07-17
RU2769694C2 (ru) 2022-04-05

Similar Documents

Publication Publication Date Title
US10829479B2 (en) C5-anilinoquinazoline compounds and their use in treating cancer
RU2656597C2 (ru) Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста
AU2016323399B2 (en) 8-(6-(3-(amino)propoxy)-3-pyridyl)-1 -isopropyl-imidazo(4,5-c)quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase for the treatment of cancer
JP2025532125A (ja) 新規なテトラヘテロサイクル化合物
ES2688396T3 (es) Compuestos de 1,3,4,tiadiazol y su uso en el tratamiento del cáncer
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
CA3080910A1 (en) Compounds useful for inhibiting cdk7
EP3615526B1 (en) Phenoxyquinazoline compounds and their use in treating cancer
Hou et al. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors
EP3441387A1 (en) Pi3k inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer
WO2025149623A1 (en) Wnk1 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)